Desbac

(Cefpodoxime Proxetil USP Capsule/Suspension)

Presentation :

Desbac Capsule : Each capsule contains Cefpodoxime Proxetil USP 130 mg equivalent to Cefpodoxime 100 mg.

Desbac Suspension : Each 5 ml reconstituted suspension contains Cefpodoxime Proxetil USP equivalent to Cefpodoxime 40 mg.

Indications :

Cefpodoxime is indicated for the treatment of the following diseases :

Upper respiratory tract infections : Acute otitis media, Sinusitis, Pharyngitis and Tonsillitis

Lower respiratory tract infections : Acute community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis

Upper & lower urinary tract infections : Cystitis, Pyelonephritis

Skin & soft tissue infections : Abscesses, Cellulitis, Infected wounds, Furuncles, Folliculitis, Paronychia, Carbuncles and Ulcers

Sexually transmitted diseases : Acute uncomplicated urethral & cervical gonorrhea, Acute ano-rectal infections in women caused by *N. gonorrhoeae*

Dosage and administration :

Adults (>13 years) :

Type of infections	Total daily dose	Dose frequency (Days)	Duration
Acute, community-acquired pneumonia	400 mg	200 mg 12 hrly	14
Acute bacterial exacerbation of chronic bronchitis		400 mg	200 mg 12 hrly 10
Uncomplicated gonorrhea (men & women)		200 mg	Single dose
Rectal gonococcal infections (women)		200 mg	Single dose
Skin and skin structure	800 mg	400 mg 12 hrly	7-14
Pharyngitis/tonsillitis	200 mg	100 mg 12 hrly	5-10
Uncomplicated UTI	200 mg	100 mg 12 hrly	7

Children :

15 days - 6 month : 8mg/kg/day in two divided doses

6 month - 2 years : 5 ml twice daily

3 - 8 years : 10 ml twice daily

Above 9 years : 12.5 ml or 100 mg capsule twice daily.

Contraindications :

Cefpodoxime proxetil is contraindicated in patients with a known allergy to Cefpodoxime or to the Cephalosporin group of antibiotics.

Precautions :

The total daily dose of Cefpodoxime proxetil should be reduced in patients with transient or persistent reduction in urinary output due to renal insufficiency. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other broad-spectrum antibiotics, prolonged use of Cefpodoxime proxetil may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential.

Use in pregnancy and lactation :

Cefpodoxime was neither teratogenic nor embryocidal in animal trial. There is, however, no adequate and well-controlled study of Cefpodoxime proxetil use in pregnant women. The drug should be used during pregnancy only if clearly needed. As Cefpodoxime is excreted in human milk, a decision should be made whether to discontinue breast-feeding or to discontinue the drug.

Side-effects :

Cefpodoxime is generally well tolerated. Possible side effects include gastrointestinal disorders such as diarrhoea, nausea, vomiting, abdominal pain, rash, urticaria and itching. Occasional cases have been reported of headaches, dizziness, tinnitus, parethesia, asthenia, and malaise.

Drug interactions :

Antacids : Concomitant administration of high doses of antacids (sodium bicarbonate and aluminium hydroxide) or H2 blockers reduces peak plasma level by 24% to 42% and the extent of absorption by 27% to 32%, respectively. *Probenecid :* Renal excretion of Cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak Cefpodoxime levels. *Nephrotoxic drugs :* Close monitoring of renal function is advised when Cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.

Commercial Pack :

Desbac Capsule : Each box contains 3 alu-alu blister strips of 4 Capsules.

Desbac Suspension : Each bottle contains cefpodoxime proxetil powder to be reconstituted into 50 ml suspension.

GENERAL ***Pharmaceuticals Ltd.***
Gazipur, Bangladesh.